Loading…
Daré Bioscience, Inc. is projected to decline to $1.19 by 2027, a -7% move from its current price of $1.28. DARE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.23 | $1.28 | $1.34 | +0.02% |
| Aug 6 | $1.20 | $1.28 | $1.36 | +0.04% |
| Aug 7 | $1.19 | $1.28 | $1.38 | +0.06% |
| Aug 8 | $1.18 | $1.28 | $1.40 | +0.08% |
| Aug 9 | $1.16 | $1.28 | $1.41 | +0.09% |
| Aug 10 | $1.15 | $1.28 | $1.42 | +0.11% |
| Aug 11 | $1.14 | $1.28 | $1.44 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.14 | $1.28 | $1.44 | +0.13% |
| Week 2 | $1.09 | $1.28 | $1.51 | +0.26% |
| Week 3 | $1.06 | $1.29 | $1.57 | +0.40% |
| Week 4 | $1.02 | $1.29 | $1.62 | +0.53% |
| Week 5 | $0.9988 | $1.29 | $1.66 | +0.66% |
| Week 6 | $0.9761 | $1.29 | $1.71 | +0.80% |
| Week 7 | $0.9558 | $1.29 | $1.75 | +0.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Daré Bioscience, Inc. is a healthcare company that develops therapies in contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Its product portfolio includes XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis, and Ovaprene, a hormone-free monthly intravaginal contraceptive. It also develops Sildenafil Cream for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for dyspareunia; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. The company also develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth.
Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Daré Bioscience, Inc. (DARE) is currently trading at $1.19 with a market capitalization of $17.75M and a rank of 4695 in its market segment.
The near-term technical picture shows mixed momentum in a small-cap healthcare context, with sentiment labeled NEUTRAL and a current price around the lower end of the range.
The long-run forecast paints a path of rising value, with the 2030 average price at $1.56 and a substantial upside by 2050 to $6.00 on average and up to $13.29 on the high end, signaling meaningful upside over the coming decades. The forecast also shows a progression of bullish sentiment from 2030 onward, with notable ROI expansion through 2050 (2030 ROI 31.4%, 2040 ROI 137.6%, 2050 ROI 406.7%).
A major floor 60.4% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 69.5% above — a clean break opens room to run.
A major ceiling 155.5% above — clearing it would confirm fresh momentum.
Key DARE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DARE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.22 | Buy | $1.24 | Buy |
| MA 10 | $1.25 | Buy | $1.34 | Sell |
| MA 20 | $1.64 | Sell | $1.54 | Sell |
| MA 50 | $1.93 | Sell | $1.82 | Sell |
| MA 100 | $1.99 | Sell | $1.93 | Sell |
| MA 200 | $1.94 | Sell | $2.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.21 | Buy |
| Stoch RSI (14) | 29.17 | Neutral |
| CCI (20) | -71.31 | Neutral |
| Williams %R (14) | -93.41 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -41.06 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 6.59 | Buy |
| TRIX (15) | -1.47 | Sell |
| Awesome (5,34) | -0.60 | Sell |
| Ultimate (7,14,28) | 36.79 | Neutral |
| Momentum (10) | -0.74 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.19 | Buy |
| ADX (14) | 30.90 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is Neutral, with a cautious tilt near-term given modest price action and mixed momentum indicators.
RSI(14) sits at 30, suggesting relatively subdued momentum, and price action is trading between key moving averages.
The SMA50 is $2.05 and the SMA200 is $1.96, providing nearby resistance and support dynamics around a current price of $1.19. The explicit support level sits at $1.22, while resistance stands at $2.17. The 30-day range has traded between $0.8996 and $1.56, highlighting limited upside within the immediate window. Annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.16 | $1.28 | $1.78 | 0% | Neutral | |
| $0.9012 | $1.19 | $1.69 | -7% | Neutral | |
| $0.8858 | $1.23 | $1.84 | -4% | Neutral | |
| $0.9603 | $1.39 | $2.17 | +8% | Neutral | |
| $1.09 | $1.64 | $2.65 | +28% | Bullish | |
| $1.34 | $2.07 | $3.45 | +61% | Bullish | |
| $1.23 | $1.97 | $3.37 | +54% | Bullish | |
| $1.12 | $1.83 | $3.22 | +43% | Bullish | |
| $1.25 | $2.11 | $3.78 | +65% | Bullish | |
| $1.09 | $1.89 | $3.46 | +47% | Bullish | |
| $1.49 | $2.95 | $5.87 | +130% | Bullish | |
| $2.84 | $6.32 | $14.18 | +394% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.16 | $1.28 | $1.58 | +0.00% |
| September 2026 | $1.05 | $1.26 | $1.58 | -1.34% |
| October 2026 | $1.07 | $1.30 | $1.65 | +3.12% |
| November 2026 | $1.13 | $1.38 | $1.77 | +6.03% |
| December 2026 | $1.10 | $1.37 | $1.78 | -1.09% |
Click any year to see its month-by-month DARE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Daré Bioscience, Inc.'s 2026 outlook centres on $1.28, within a $1.16 to $1.78 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DARE could reach as high as $1.69, with a base case around $1.19 and support toward $0.9012 — roughly -7% from $1.28. Price action looks broadly range-bound.
Expect DARE to range from $0.8858 to $1.84 through 2028. The $1.23 average target implies a -4% move from current prices. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
The DARE price prediction for 2029 points to an average of $1.39 (low $0.9603, high $2.17) — a potential gain of +8% on today's $1.28. Price action looks broadly range-bound.
In 2030, DARE is projected to trade between $1.09 and $2.65, averaging $1.64 — a potential gain of +28% from today's $1.28. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Daré Bioscience, Inc.'s 2031 outlook centres on $2.07, within a $1.34 to $3.45 range. That is up +26% on the projected 2030 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2032, DARE could reach as high as $3.37, with a base case around $1.97 and support toward $1.23 — roughly +54% from $1.28. Buyers look set to stay in control over this stretch.
Expect DARE to range from $1.12 to $3.22 through 2033. The $1.83 average target implies a +43% move from current prices. That is -7% versus the projected 2032 average. Momentum favours further upside here.
The DARE price prediction for 2034 points to an average of $2.11 (low $1.25, high $3.78) — a potential gain of +65% on today's $1.28. Buyers look set to stay in control over this stretch.
In 2035, DARE is projected to trade between $1.09 and $3.46, averaging $1.89 — a potential gain of +47% from today's $1.28. That is -10% versus the projected 2034 average. Momentum favours further upside here.
Daré Bioscience, Inc.'s 2040 outlook centres on $2.95, within a $1.49 to $5.87 range. That is up +56% on the projected 2035 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DARE could reach as high as $14.18, with a base case around $6.32 and support toward $2.84 — roughly +394% from $1.28. Momentum favours further upside here.
Investing $1,000 in DARE today (≈ 781.25 DARE) could be worth
$4,938.3
+$3,938.3 (+394%) by 2050 · US Dollar
Based on the average projected DARE price of $6.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DAREwould be worth at today's price.
$1,000 invested in DARE on Jul 31, 2025 (≈ 416.66665 DARE) would be worth
$533.33
-$466.67 (-46.7%) today · 0.53× · US Dollar
Based on a DARE entry price of $2.4 vs. today's $1.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.28 | $1,000 | +0.0% |
| 1 month ago | $2.11 | $606.64 | -39.3% |
| 3 months ago | $2.34 | $547.01 | -45.3% |
| 6 months ago | $1.76 | $727.27 | -27.3% |
| 1 year ago | $2.4 | $533.33 | -46.7% |
| All time (5.0y) ago | $18.48 | $69.26 | -93.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DARE forecast.
Our base-case forecast reaches $2.60 around 2040.
Implied market cap at $2.60: $38.95M
The multi-year forecast presents a bullish arc beginning in 2030, with the 2030 average price at $1.56 and a 31.4% ROI, followed by continued upside in subsequent years: 2031 avg $1.94 (ROI 63.5%), 2032 avg $1.84 (ROI 54.9%), 2033 avg $1.75 (ROI 47.4%), and 2034 avg $2.00 (ROI 68.6%). By 2040, the average price is forecast at $2.82 with a 137.6% ROI, and by 2050, the average is $6.00 with a 406.7% ROI and a max projected price of $13.29.
The outlook remains bullish through 2050, with sentiment labeled BULLISH in the later years and substantial upside potential reflected in the high max forecast. However, there are years with weaker performance in the near term (for example 2027 avg $1.12 with a -5.7% ROI and 2028 avg $1.15 with a -2.6% ROI), illustrating that the path involves volatility and uncertainty alongside the upside. The numbers also imply a high-volatility environment, consistent with a small-cap healthcare company exploring multiple product candidates and therapies.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.56 with a range from a low of $1.05 to a high of $2.51 and an ROI of 31.4%. The sentiment is BULLISH.
The forecast indicates a bullish long-term path with rising average prices and positive ROI in several years (notably 2030, 2031–2035, 2040, and 2050). Near-term years such as 2027 and 2028 show negative ROI, and the near-term view is NEUTRAL with higher volatility (80%), so outcomes are uncertain and not guaranteed.
Yes, the forecast shows higher upside in later years, with a 2040 max price of $5.54 and a 2050 max of $13.29; thus a $5 level would be within the forecast path by 2040 at the latest.
Current price is $1.19 and market cap is $17.75M.
The 30-day snapshot shows Neutral sentiment, RSI(14) at 30, SMA50 at $2.05, SMA200 at $1.96, with support at $1.22 and resistance at $2.17. The 30-day range is $0.8996 to $1.56, and annualized volatility is 80%.
Daré Bioscience, Inc. Community Discussion
0Share your Daré Bioscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.